Evidence map›Paper›PMID 30186570›Full record

ArticleIranian journal of basic medical sciences2018

Shahrzad Havakhah, Mojtaba Sankian, Gholam Hosein Kazemzadeh, Keyvan Sadri, Hamid Reza Bidkhori, Hojjat Naderi-Meshkin, Alireza Ebrahimzadeh Bideskan, Saeed Niazmand, Ahmad Reza Bahrami, Abolfazl Khajavi Rad

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shahrzad HavakhahDepartment of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mojtaba SankianImmunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gholam Hosein KazemzadehDepartment of Vascular Surgery, Vascular and Endovascular Surgery Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Keyvan SadriNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid Reza BidkhoriStem Cell and Regenerative Medicine Research Department, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran.
Hojjat Naderi-MeshkinStem Cell and Regenerative Medicine Research Department, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran.
Alireza Ebrahimzadeh BideskanMicroanatomy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Saeed NiazmandDepartment of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ahmad Reza BahramiStem Cell and Regenerative Medicine Research Department, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran.
Abolfazl Khajavi RadDepartment of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRImam Reza Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesRenal ischemia-reperfusion injury (IRI) as a severe condition of acute kidney injury (AKI) is the most common clinical problem with high mortality rates of 35-60% deaths in hospital. Mesenchymal stem cells (MSC) due to unique regenerative characteristics are ideal candidates for the treatment of the ischemic injuries. This work is focused on the administration of MSC to IRI-induced AKI Wistar rats and evaluating their significance in AKI treatment. MATERIAL AND

methodsAnimals underwent surgical procedure and AKI was induced by 40 min bilateral renal pedicle clamping. Immediately after reperfusion, 2×106 rat bone marrow derived MSCs were injected via intra-parenchymal or intra-aortic route.

resultsAnimals subjected to AKI after days 1 and 3 showed significant increase in the serum creatinine and blood urea nitrogen (BUN) concentration along with a declined glomerular filtration rate (GFR) when compared with non-ischemic animals. On the other hand, treated animals showed a significant enhanced regeneration as compared to ischemic animals in both administration route groups.

conclusionAccording to the results concluded from the renoprotective effects of MSC in IRI/AKI, MSCs could be considered as promising therapeutic approach for AKI in clinical applications.

Indexed as

Acute kidney injuryAcute renal failure Bone marrow-derived mesenchymal stem cellCell transplantation Ischemic kidney injuryRat

Identifiers

PMID30186570
PMCPMC6118091
OpenAlexW2886627249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.